Kro­nos Bio cuts a fifth of staff, ex­plores new dos­ing sched­ule for sol­id tu­mor drug

Kro­nos Bio is again re­sort­ing to cost-sav­ing mea­sures to ex­tend its cash run­way af­ter lay­ing off staff and reshuf­fling its pri­or­i­ties around four months ago …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.